Skip to main content

The Money Overview

Seniors on both Medicare and Medicaid with the lowest incomes would owe nothing for generic drugs starting in 2028 under a CMS proposal released October 16

The $1 copay for generic drugs would drop to $0 for the lowest-income people who have both Medicare and Medicaid, beginning with plan years that start January 1, 2028. The change is part of a proposed rule the Centers for Medicare & Medicaid Services released October 16, and it is still a proposal, not a final rule.

The cut is described in a CMS fact sheet on proposed rule CMS-4214-P, which says the agency would lower the generic drug copayment from $1 to $0 for full-benefit dual eligible individuals at or below 100% of the federal poverty level. The rule carries out sections 6219, 6220 and 6224 of the Consolidated Appropriations Act, 2026, which was signed February 3, 2026.

Who would stop paying the $1

The group is narrower than everyone on both programs. CMS limits the proposal to full-benefit dual eligible individuals, meaning people who get full Medicaid coverage along with Medicare, whose income is at or below the federal poverty level. People with Medicare and partial Medicaid help, or with incomes above that line, are not part of this change as CMS describes it.

The fact sheet does not describe any change to brand-name or other drug copays, and it does not give a count of how many people would be affected. CMS’s announcement says the wider rule touches Medicare Advantage plans, Part D plans and pharmacy benefit managers, along with enrollees, including low-income Medicare beneficiaries who would get enhanced cost-saving protections.

For anyone in that group, the practical question is when the $0 would reach them and what has to happen first. Nothing changes in 2027. The $0 generic copay would apply only to plan years starting January 1, 2028, and only if CMS finalizes the rule as proposed.

Retirement deadlines, in your inbox: Miss an enrollment or claim deadline and the money can be gone. Join the Retirement Money Brief and we’ll send you our Prescription Coverage & Pharmacy Checklist as a welcome gift.

Get the Brief + the prescription checklist →

We may earn a commission from links on this page.

What happens between the proposal and 2028

CMS says in its announcement that the proposal will be open for public comment for 60 days after it is published in the Federal Register. The Federal Register publication date has not been announced, so the comment deadline is not yet set.

The same announcement says CMS expects to release another proposed rule with policy and technical changes for Medicare Advantage and Part D later this fall. That second rule would be a separate proposal with its own comment period.

A proposed rule can change before it is final, and the copay change depends on the final text. The start the fact sheet gives for the generic copay is plan years beginning January 1, 2028, and the announcement ties the whole package to contract year 2028 for Medicare Advantage and Part D.

What else the rule would change for plan members

The $0 copay is one of three pieces. Section 6220, the REAL Health Providers Act, covers Medicare Advantage provider directories. Under the proposal, plans would have to verify and update directory information at least every 90 days and report an accuracy score to CMS, starting in contract year 2028. Enrollees who get out-of-network care because of an inaccurate directory listing would pay no more than their in-network cost sharing.

For contract year 2029, the fact sheet says CMS would publicly display the accuracy scores in a machine-readable format, and plans would have to show those scores prominently in their directories. CMS Administrator Mehmet Oz said in the announcement that “CMS has been working to improve data connectivity and accuracy in provider directories across the healthcare system.”

Section 6224 deals with pharmacy benefit managers, which work with Part D plans on drug payments. PBMs would report their compensation and cost performance to plan sponsors and CMS each year, and their payments would reflect the fair market value of services rather than drug costs. Enforcement could include disgorgement of funds to CMS for violations of the remuneration requirements.

What dual eligible people can use today

People with full Medicaid coverage already get Extra Help with Part D costs automatically, according to Medicare.gov’s page on help with drug costs. The same is true for people who get state help paying Part B premiums through a Medicare Savings Program or who receive Supplemental Security Income. Others can apply through Social Security, which describes Extra Help as a program for people with limited income and resources that lowers Part D costs, with applications online or at 1-800-772-1213.

Medicare.gov also says people with Medicaid or Extra Help can change their coverage once a calendar month, which includes switching to a different Medicare drug plan. Annual enrollment, from October 15 through December 7, is the other route to a new plan for 2027.

The open question for the lowest-income dual eligible households is what they pay on generics between now and January 1, 2028, and whether the proposal reaches final form before then. Until CMS publishes the final rule, the copays in each member’s current plan documents remain the ones that apply.

Paying for generics on Medicare and Medicaid until 2028?

A proposal for 2028 does nothing for the drug bills due before then, and the help that applies now differs by state, which is where a missed program costs real money.

The Medicare Cost & Coverage Protection Kit includes 51 state Medicare cost-help packs and covers the new Part D out-of-pocket cap. The turn is from the story’s question about a 2028 copay to the programs that cut Medicare drug and premium costs today.

Get the state Medicare cost-help pack and Part D cap guide in the Protection Kit →


More Financial Reading

This article was produced with AI assistance and edited for accuracy against the sources linked above.

Avatar photo

Daniel Harper

Daniel is a finance writer covering personal finance topics including budgeting, credit, and beginner investing. He began his career contributing to his Substack, where he covered consumer finance trends and practical money topics for everyday readers. Since then, he has written for a range of personal finance blogs and fintech platforms, focusing on clear, straightforward content that helps readers make more informed financial decisions.​


More in Government & Policy